Development of a highly sensitive ELISA for determination of darunavir in plasma samples using a polyclonal antibody with high affinity and specificity-Reference-Cited by-同舟云学术

Development of a highly sensitive ELISA for determination of darunavir in plasma samples using a polyclonal antibody with high affinity and specificity

Published:2020-03 Issue:6 Volume:12 Page:355-366
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Almehizia Abdulrahman A¹,Herqash Rashed N¹²,Darwish Ibrahim A¹

Affiliation:

1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

2. Medicinal Aromatic and Poisonous Plant Research Center, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

Abstract

Aim: To support pharmacokinetic studies and therapeutic monitoring of darunavir (DRV), a highly sensitive ELISA was developed for the determination of DRV in plasma samples at picogram levels. Results: The assay LOD and LOQ were 15 and 30 pg ml-1, respectively. The working range of the assay was 20–2000 pg ml-1. Analytical recoveries of DRV from spiked plasma were in the ranges of 98.4–113.0 and 86.0–99.1% for intra-assay and inter-assay runs, respectively. The precision of the assay was satisfactory. Conclusion: The ELISA is characterized by high throughput and it is expected to significantly contribute to routine analysis of DRV in its pharmacokinetic studies and therapeutic monitoring.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2020-0034

Reference33 articles.

1. Aldrich R, Garry W. Who's Who in Gay and Lesbian History: From World War II to the Present Day. Aldrich R Wotherspoon G (Eds). Routledge, London, 152–175 (2001).

2. U.S. Food and Drug Administration. HIV/AIDS historical time line 1981–1990. (2019). https://www.fda.gov/patients/hiv-timeline-and-history-approvals/hivaids-historical-time-line-1981-1990

3. Discovery of Novel, Non-Peptide HIV-1 Protease Inhibitors by Pharmacophore Searching

4. Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

5. Decline in the AIDS and death rates in the EuroSIDA study: an observational study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Darunavir: A comprehensive profile;Profiles of Drug Substances, Excipients and Related Methodology;2021

2. Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir;Molecules;2020-09-07